Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | NQO2 | P16083 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160600 | 1.00 | ALDH1A1 (0.58) | ALDH1A1RAB9AKDM4EKMT2AMEN1 | |
| SCHEMBL30717271 | 0.87 | KMT2A (0.68) | ALDH1A1RAB9AKDM4EKMT2AMEN1 | |
| SCHEMBL31399998 | 0.87 | ALDH1A1 (0.68) | ALDH1A1RAB9AKDM4EKMT2AMEN1 | |
| SCHEMBL30717270 | 0.87 | KMT2A (0.68) | ALDH1A1RAB9AKDM4EKMT2AMEN1 | |
| SCHEMBL1160711 | 0.87 | KMT2A (0.68) | ALDH1A1RAB9AKDM4EKMT2AMEN1 | |
| SCHEMBL30717269 | 0.87 | KMT2A (0.68) | ALDH1A1RAB9AKDM4EKMT2AMEN1 | |
| SCHEMBL1160610 | 0.87 | ALDH1A1 (0.68) | ALDH1A1RAB9AKDM4EKMT2AMEN1 | |
| SCHEMBL13728348 | 0.81 | KDM4E (0.59) | ALDH1A1RAB9AKDM4EKMT2AMEN1 | |
| SCHEMBL14734394 | 0.81 | KDM4E (0.59) | ALDH1A1RAB9AKDM4EKMT2AMEN1 | |
| SCHEMBL4928239 | 0.81 | ALDH1A1 (0.59) | ALDH1A1RAB9AKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2540350-B1 | COMBINATIONS OF A MACROCYCLIC QUINOXALINE COMPOUND WHICH IS AN HCV NS3 PROTEASE INHIBITOR WITH OTHER HCV AGENTS | MERCK SHARP & DOHME (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2540350-B1 | COMBINATIONS OF A MACROCYCLIC QUINOXALINE COMPOUND WHICH IS AN HCV NS3 PROTEASE INHIBITOR WITH OTHER HCV AGENTS | MERCK SHARP & DOHME (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2540349-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A MACROCYCLIC QUINOXALINE COMPOUND WHICH IS AN HCV NS3 PROTEASE INHIBITOR | MERCK SHARP & DOHME (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2540349-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A MACROCYCLIC QUINOXALINE COMPOUND WHICH IS AN HCV NS3 PROTEASE INHIBITOR | MERCK SHARP & DOHME (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2540350-A1 | Combinations of a macrocyclic quinoxaline compound which is an HCV NS3 protease inhibitors with other HCV agents | Merck Sharp & Dohme Corp. (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2540350-A1 | Combinations of a macrocyclic quinoxaline compound which is an HCV NS3 protease inhibitors with other HCV agents | Merck Sharp & Dohme Corp. (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2540349-A1 | Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an HCV NS3 protease inhibitor | Merck Sharp & Dohme Corp. (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2540349-A1 | Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an HCV NS3 protease inhibitor | Merck Sharp & Dohme Corp. (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2310095-B1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2310095-B1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20110224134-A1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-09-15 | — | — | US | disclosed |
| US-20110224134-A1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-09-15 | — | — | US | disclosed |
| US-7973040-B2 | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973040-B2 | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973040-B2 | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2310095-A1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20100029666-A1 | Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-02-04 | — | — | US | disclosed |
| US-20100029666-A1 | Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-02-04 | — | — | US | disclosed |
| US-20100029666-A1 | Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-02-04 | — | — | US | disclosed |
| WO-2010011566-A1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224134-A1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | KEAP1, CTSC, SPINT2 | ALDH1A1 1419/4885RAB9A 1568/4885KDM4E 1621/4885 |
| US-20100029666-A1 | Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors | KEAP1, CTSC, SPINT2 | ALDH1A1 1419/4885RAB9A 1568/4885KDM4E 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.